| 1 |
25752914 | Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. | 2015 Aug |
7 |
| 2 |
19890215 | CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. | 2010 Jul |
4 |
| 3 |
19246729 | Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. | 2009 Mar |
1 |
| 4 |
19916992 | Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. | 2009 Nov |
2 |
| 5 |
17922881 | Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. | 2008 Apr |
5 |
| 6 |
16842404 | The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. | 2006 Aug |
1 |
| 7 |
16170225 | Will pharmacogenomic discoveries improve HIV therapeutics? | 2005 Aug-Sep |
1 |
| 8 |
16267764 | Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. | 2005 Dec 1 |
3 |
| 9 |
15448116 | Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. | 2004 Dec |
6 |
| 10 |
11399981 | Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. | 2001 May 25 |
1 |
| 11 |
9660842 | Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. | 1998 Jul |
2 |